Guggenheim Maintains Buy on AbbVie, Raises Price Target to $322
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $288 to $322.
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $288 to $322.